Search

You searched for "radiological"

543 results found

Long-term oncologic outcomes of salvage cryoablation for rrPC

1 July 2017 | | Urologic Oncology
Of patients undergoing radiotherapy (RT) for prostate cancer (PC), at least 15-20% will experience recurrence. Although salvage prostatectomy achieves durable oncological outcomes at 10 years, it is associated with significantly high morbidity. Thus, the majority of men with radio-recurrent prostate...

Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for SCC

1 July 2015 | | Basic Science Research | urinary bladder, carcinoma, squamous cell, cystectomy, schistosomiasis, biological markers
Squamous cell carcinoma (SCC) of the bladder is more commonly seen in Egypt due to schistosomiasis (bilharziasis) and accounts for 2% to 5% of all bladder tumours. Schistosomiasis is found in the bladder vasculature and leads to chronic inflammation causing...

Local tumour bed recurrence following partial nephrectomy

1 September 2018 | | Reconstructive Urology, Urologic Oncology | kidney neoplasms, local, neoplasm recurrence, neoplasm staging, nephrectomy, risk factors
In this interesting retrospective study, the authors looked at the incidence of local tumour bed recurrence after partial nephrectomy (PN), the factors associated with that, and the management. A total of 2,271 patients’ charts were reviewed who underwent partial nephrectomies...

PIRADS-3 lesions and clinically significant prostate cancer – what are we missing?

5 December 2022 | | Urologic Oncology | MRI, biopsy, fusion biopsies, prostate cancer, radical prostatectomy, risk, systematic biopsies, targeted biopsies
The use of pre-biopsy MRI has definitely enhanced our decision making in managing patients with suspected prostate cancer (PCa). There is still uncertainty around the outcomes for patients with PIRADS-3 lesions, with a small but definite risk of missing clinically...

Visual-estimation (cognitive), image-fusion (software) and in-bore targeted prostate biopsy: is there an optimal approach?

3 March 2021 | | Urologic Oncology, Technological Developments
The diagnostic superiority of multiparametric magnetic resonance imaging (mpMRI) prior to targeted and systematic prostate biopsy over systematic transrectal ultrasound-guided (TRUS) biopsy alone in the detection of clinically significant prostate cancer (csPCa) has been proven by multiple level 1 studies...

Technology for remote working and COVID-19 resources

2 April 2020 | | COVID-19 - Urology News
The COVID-19 pandemic has altered every aspect of how we live, and how healthcare needs to be provided for the welfare of patients and staff. I thought I would try to summarise a few potential technology tools that could be...

BXTAccelyon becomes global distribution partner for new online prostate MRI self-learning tool to enhance prostate cancer diagnosis

6 May 2020 | Contracts & Distributors
BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide, and distribution partner for PrecisionPoint™, the...

The role of PET-CT imaging in prostate cancer

4 October 2021 | | Urologic Oncology
Prostate cancer (PCa) is the second most common cancer in the UK, with 43,000 cases in 2017-18 [1,2]. Accurate primary staging and the detection of suspected recurrence following treatment is vital for directing management and predicting prognosis. This has conventionally...

Demanding cases or nightmares in uro-oncology? Jan/Feb 2023

6 January 2023 | | Urologic Oncology
Radical surgical treatment of prostate cancer has become minimally invasive owing to robotic assisted laparoscopic technology [1]. Patients who undergo robotic assisted radical prostatectomy (RARP) often have lower risk of morbidity compared to an open approach. However, patients with a...

Recent developments in bladder cancer – NMIBC

3 May 2022 | | Urologic Oncology
Every year, roughly 10,300 individuals are diagnosed with bladder cancer in the UK, making it the 11th most common cancer in the UK, and the eighth most common cancer in men [1]. Of those diagnosed with the disease, 75-85% will...

What did the Romans ever do for us?

1 May 2016 | | Technological Developments
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). Previously in this column, I told you about the Saxons and how they...

Understanding Stauffer’s syndrome

1 May 2018 | | Andrology, Basic Science Research, Endourology and Stones, Functional Urology, Infection, Neurourology, Paediatric Urology, Technological Developments, Trauma and Emergency Urology, Urologic Oncology, Uroradiology
Who was Stauffer and what is Stauffer’s syndrome? Maurice Stauffer (1915-1994) was a gastroenterologist at the Mayo Clinic in Rochester, United States, and in 1961 first characterised the non-metastatic, paraneoplastic effects of renal cell carcinoma (RCC) on liver size and...